Clinical Trials Browser

Active not recruiting × OTHER × Inflammatory Breast Neoplasms × Clear all

NCT02876107 2026-04-15

Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer

Phase 2 Active not recruiting

Breast Neoplasms, Edema, Erythema, Inflammatory Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01525966 2026-03-30

Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer

Phase 2 Active not recruiting

67 enrolled 12 charts

Breast Neoplasms, Inflammatory Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05383196 2026-02-11

Onvansertib + Paclitaxel In TNBC

Phase 1/2 Active not recruiting

Breast Neoplasms, Inflammatory Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02876302 2026-02-04

Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer

Phase 2 Active not recruiting

23 enrolled 18 charts

Breast Neoplasms, Inflammatory Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02411656 2026-01-23

Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy

Phase 2 Active not recruiting

71 enrolled 11 charts

Edema, Erythema, Inflammatory Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02971748 2026-01-22

Pembrolizumab in Treating Patients With Hormone Receptor Positive, Localized Inflammatory Breast Cancer Who Are Receiving Hormone Therapy and Did Not Achieve a Pathological Complete Response to Chemotherapy

Phase 2 Active not recruiting

36 enrolled 8 charts

Inflammatory Breast Neoplasms

NCT03202316 2025-12-16

Atezolizumab, Cobimetinib, and Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer

Phase 2 Active not recruiting

Inflammatory Breast Neoplasms

NCT02623972 2025-11-25

A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer

Phase 2 Active not recruiting

22 enrolled 12 charts

Inflammatory Breast Neoplasms

NCT00295893 2025-09-25

Combination Chemotherapy With or Without Trastuzumab in Treating Patients With Stage II or Stage III Breast Cancer

Phase 2 Active not recruiting

121 enrolled 10 charts

Breast Neoplasms, Carcinoma, Ductal, Breast, Carcinoma, Lobular, Breast Neoplasms, Male, Inflammatory Breast Neoplasms

NCT03515798 2025-09-12

PELICAN

Phase 2 Active not recruiting

Inflammatory Breast Neoplasms

NCT01730833 2025-06-03

Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer

Phase 2 Active not recruiting

63 enrolled 11 charts

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT02221999 2023-08-29

SHPD002

Phase 2/3 Active not recruiting

Carcinoma, Ductal, Breast, Inflammatory Breast Neoplasms

NCT03012100 2023-01-13

Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer

Phase 2 Active not recruiting

Unilateral Breast Neoplasms, Breast Neoplasms, Inflammatory Breast Neoplasms, Triple Negative Breast Neoplasms